Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.22.2.2
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 16, 2020
Nov. 01, 2006
Feb. 28, 2009
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Licensing and other arrangements                  
Revenue from contracts with customers       $ 25   $ 550 $ 3,300 $ 1,094  
Takeda | Collaboration Agreement                  
Licensing and other arrangements                  
Revenue from contracts with customers $ 2,000     0 $ 800 $ 0 800 $ 0  
Contract assets       0     0   $ 0
Contract liabilities       0     0   0
Capitalized contract costs       0     0   $ 0
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       $ 16,000     $ 16,000    
Takeda | Collaboration Agreement | TAK-079                  
Licensing and other arrangements                  
Royalty payment period   13 years 6 months              
Royalty payment period from the first commercial sale of each royalty-bearing discovery product   12 years              
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 19,000              
Takeda | Collaboration Agreement | Other antibodies                  
Licensing and other arrangements                  
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300            
Royalty payment period     10 years